• BreezeBio

  Participated · Series B · Feb 2026

  BreezeBio, formerly GenEdit, engineers polymer-based NanoGalaxy nanoparticles that deliver genetic payloads such as mRNA with cell-type precision across immune, cardiac, pulmonary and central nervous system tissues. The company has shifted from being solely a delivery-technology provider to building a therapeutic pipeline concentrated on autoimmune disease and oncology. Its lead candidate, BRZ-101, delivers autoantigen-encoding mRNA and tolerogenic co-factors to antigen-presenting cells to induce antigen-specific regulatory T cells and aims to restore immune tolerance in type 1 diabetes; the program is now entering IND-enabling studies after positive preclinical results in mice and non-human primates. BreezeBio is also extending NanoGalaxy with ligand conjugation to reach T cells and enable in vivo CAR-T therapies. Beyond internal programs, the firm maintains a multi-year collaboration and licensing agreement with Genentech that has already produced an initial milestone payment. The recent financing strengthens its balance sheet, allowing continued platform expansion and clinical advancement of its pipeline.

• Syntracts

  Participated · Seed · Oct 2025

  Syntracts offers a privacy-first infrastructure layer that plugs into law firms’ existing systems (e.g., iManage, NetDocs, SharePoint) to ingest documents, structure their contents, and feed the resulting data back into any dashboard or AI assistant in use. Its specialized language models are fine-tuned on synthetic data generated from each client’s own contracts, reducing review time by 80% while ensuring outputs remain auditable and confined to the firm’s on-prem environment. Unlike cloud-hosted legal AI tools, all processing happens entirely within the customer’s firewall, addressing the sector’s stringent confidentiality and reliability requirements. The company has secured multi-year partnerships with AmLaw 25 firms and was accepted into A&O Shearman’s Fuse incubator, underscoring early market traction. With fresh seed funding, Syntracts plans to accelerate adoption across BigLaw and corporate legal departments and further develop its secure AI backbone. The Washington, D.C.–based startup was co-founded by former Uber AI Labs CTO Doug Bemis and Big Law veteran Christopher Martin. To date, it has raised $5.3 million and is backed by investors focused on frontier AI and enterprise infrastructure.

• Ryght AI

  Participated · Seed · Jun 2025

  Ryght AI delivers an intelligent software platform powered by "AI Site Twins," dynamic data models that replicate every clinical research site worldwide in real time. The system ingests historical performance, patient-demographic and operational data to help life-sciences sponsors and contract research organizations more accurately run trial-feasibility analyses, choose optimal sites, forecast enrollment and streamline site-activation workflows. Built with generative and agentic AI and certified as SOC Type 2 compliant, the platform enables secure, real-time collaboration among sponsors, CROs and research sites. By shortening the traditionally manual processes of site selection and patient recruitment, Ryght AI aims to reduce costly delays and speed new therapies to market. The company is positioning its technology as a foundational layer that integrates with broader enterprise systems used by pharmaceutical and biotech firms. Ryght AI’s go-to-market strategy includes partnerships with global technology and consulting leaders to scale adoption across the industry.

• Hedera Dx

  Participated · Series A · May 2025

  Hedera Dx develops blood-based liquid biopsy solutions and an AI-native platform that integrates advanced molecular diagnostics with clinical data to inform treatment decisions and support drug development. The company’s offering is designed for hospital in-house testing, aiming to make sophisticated molecular diagnostics locally affordable and easy to adopt. Its platform is already deployed across 11 European countries and the team comprises more than 20 professionals with expertise in genomics, oncology, bioinformatics, AI, and digital health. Hedera positions its real-world data capabilities as a way to generate patient-centric insights that can fuel next-generation oncology treatments. The company was founded in 2021 and is based in Lausanne. The Series A will support continued commercial expansion and further development of its real-world data infrastructure. Hedera Dx develops a blood-based liquid biopsy assay paired with end-to-end software (Hedera Prime) registered as an IVD medical device to enable hospital labs to run clinically actionable cancer tests in-house. The company combines a laboratory assay and streamlined software workflow for analytics, reporting and therapy options to overcome adoption hurdles in hospital laboratories. Hedera Dx plans to launch commercially in the autumn and to implement the first phase of a large oncology Real World Evidence (RWE) clinical testing program. The RWE program aims to create a landmark data asset on real-world usage of liquid biopsy and related cancer patient outcomes. Founded in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel, the startup positions its solution to improve access to molecular profiling and therapy selection for cancer patients. The company has just raised new funding to advance these commercialization and clinical-data objectives.

• Voxel51

  Participated · Series B · May 2024

  Voxel51 provides open-source and commercial software that enables teams to build datasets and computer vision models for machine learning and AI applications. Its open-source FiftyOne tool has been integrated into engineers' and scientists' workflows, while enterprise customers use FiftyOne Teams to securely collaborate on datasets and models. Customers span industries including automotive, robotics, security, retail and healthcare, and include LG Electronics, Berkshire Grey, Precision Planting, RIOS Intelligent Machines and Forsight. Led by CEO Brian Moore, the company sells both community and enterprise offerings to support development and deployment of computer vision systems. Voxel51 intends to use new funding to expand go-to-market operations and accelerate its product roadmap. Voxel51 develops FiftyOne, a platform and open-source tool for visualizing, analyzing and managing unstructured datasets used in computer vision and machine learning. FiftyOne launched open source in August 2020; this week Voxel51 introduced FiftyOneTeams, a fully managed edition with enterprise features like searching cloud-stored image and video datasets, dataset sharing, and version management. The company positions itself as a full‑stack data-infrastructure solution that avoids copying media or metadata onto its systems and aims to be a single source of truth for organizations’ visual data. Founders Jason Corso and machine learning PhD Brian Moore built the product to help ML engineers and data scientists verify and select data that will train models to perform desired tasks. Voxel51 says it will use new capital to further develop the platform and to double headcount from 13 to 26 employees by year-end. The company faces competitors such as Aquarium Learning and Lightly.AI but reports growth alongside rising demand for unstructured vision data. Corso declined to disclose revenue when asked. Voxel51 provides a video understanding platform for automotive, smart city and security applications. Its computer vision and deep learning models automatically identify and classify actions in video scenes and can comprehend activities and patterns. The scalable platform enables customers with large video datasets to search for specific objects, actions and behaviors and to automatically tag and integrate detected content into workflows and human decision-making processes. Founded in 2016 by University of Michigan professor Dr. Jason Corso and Dr. Brian Moore, the company is based in Ann Arbor, Mich. Voxel51 has completed a number of successful pilots in the automotive, smart city and security spaces. It closed a $2M seed round and recently concluded a $1.25M NIST grant to support development and will use the seed funds to launch its solution; total investment to date is $3.25M.

No current team members are available.